Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...

Pfizer is “evaluating appropriate next steps” for its Duchenne muscular dystrophy (DMD) gene therapy after it failed a phase 3 trial. Fordadistrogene movaparvovec (PF-06939926) was unable to ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

New data on Sarepta's gene therapy for Duchenne muscular dystrophy (DMD) has gone a long way towards building confidence in its efficacy – but have introduced a concern about its safety. Updated ...

Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy ... and exon skipping. gene. ENTR-601-44, an investigational therapy for the potential ...

A seven-year-old boy from Dublin is on his way to California to undergo testing after being diagnosed with a rare condition last year.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares began Tuesday sharply higher. Cumberland, a specialty pharmaceutical company with development efforts focused on new products for rare diseases, ...

JMP Securities reiterated their Market Outperform rating on Solid Biosciences (NASDAQ:SLDB) with a steady price target of $15.00. Currently trading at $3.04, the company has a market capitalization of ...